PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30940721-1	2019	In an interim analysis, the targeted PARP inhibitor rucaparib showed encouraging signs of disease control when used as a maintenance therapy for patients with platinum-sensitive advanced pancreatic cancer and a pathogenic mutation in BRCA1, BRCA2, or PALB2.	rucaparib	52-61	partner and localizer of BRCA2	Homo sapiens	251-256	
33970687-0	2021	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.	rucaparib	30-39	partner and localizer of BRCA2	Homo sapiens	168-173	
33970687-14	2021	CONCLUSION: Maintenance rucaparib is a safe and effective therapy for platinum-sensitive, advanced PC with a PV in BRCA1, BRCA2, or PALB2.	rucaparib	24-33	partner and localizer of BRCA2	Homo sapiens	132-137	
35205643-6	2022	Selective poly (ADP-ribose) polymerase (PARP) inhibitors such as Niraparib, Olaparib, Talazoparib, Rucaparib, and Veliparib are now approved for several cancers with loss of high-fidelity double-strand break homologous recombination (HR), namely those with deleterious mutations to BRCA1/2, PALB2, and other functionally related genes.	rucaparib	99-108	partner and localizer of BRCA2	Homo sapiens	291-296